Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
about
Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical developmentMathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development.Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.Next-generation oral preexposure prophylaxis: beyond tenofovirMaraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissuesMaraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.Clinical utility of maraviroc.CCR5 inhibitors in HIV-1 therapy.Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.Role of receptor occupancy assays by flow cytometry in drug development.Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.Model based design and analysis of phase II HIV-1 trials.Clinical relevance of CYP3A5 genotype on maraviroc exposures.A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: Figure 1
P2860
Q28084276-4DC5F1BC-B3E8-4CA4-AA06-11AB25ACC5E5Q30988835-028D4CDD-09FB-4890-8D6F-017D547F22FCQ36084912-D317BF91-AA30-4908-A3F2-90035C2A3EC9Q36558240-46D36DFA-CBE8-4977-9390-69914CFB1B09Q37067126-11FD84FE-CD3B-498D-887C-42A9CEA55C11Q37078995-FFFA12EE-7298-4145-8B2E-A9BF4B3F66D8Q37123335-E4FB2CD7-F6AF-4351-9D55-CD11083C6719Q37362444-8A921C6D-4A2F-4562-8209-96115346ADF6Q37416470-E993CDFB-E9C0-4BEA-827E-9576C76FC186Q37877242-3E6AC883-6E73-457F-BBDE-C6738DF1F7BFQ38089881-D10EE30C-9D53-435F-9E3F-6F9DED57F4E8Q38534016-9F3D3797-4C45-4F6E-BE3A-2C2E6F7C9477Q38679593-78FBE6E2-92F4-4D4D-A84C-CCE728651847Q39366403-A76D39B8-F8F5-4BE2-B150-8F163CA5918CQ42284705-55841831-FCC2-4077-BF21-15BE32BED0C3Q42592141-A2123024-E7BB-4DD0-B7F0-D3C57710D628Q43135850-F11E2112-8A91-4E19-B38F-4EEAB885DDC9Q47624840-290BE1D8-FF18-4FA1-AC66-6B1B0B5F8104Q59151022-A09CBD79-AB72-4BA5-AE86-D67A2DAA94A2
P2860
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@ast
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@en
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@nl
type
label
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@ast
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@en
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@nl
prefLabel
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@ast
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@en
Population pharmacokinetic/pha ...... cts and HIV-positive patients.
@nl
P2093
P2860
P1476
Population pharmacokinetic/pha ...... ects and HIV-positive patients
@en
P2093
Elna van der Ryst
Maria C Rosario
Philippe Jacqmin
Timothy M Jenkins
P2860
P356
10.1111/J.1365-2125.2008.03140.X
P407
P478
65 Suppl 1
P50
P577
2008-04-01T00:00:00Z